ATE540673T1 - Verwendung von a3-adenosin-rezeptor-agonisten bei der behandlung von osteoarthritis - Google Patents
Verwendung von a3-adenosin-rezeptor-agonisten bei der behandlung von osteoarthritisInfo
- Publication number
- ATE540673T1 ATE540673T1 AT06821594T AT06821594T ATE540673T1 AT E540673 T1 ATE540673 T1 AT E540673T1 AT 06821594 T AT06821594 T AT 06821594T AT 06821594 T AT06821594 T AT 06821594T AT E540673 T1 ATE540673 T1 AT E540673T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- osteoarthritis
- a3ar
- agonist
- adenosine receptor
- Prior art date
Links
- 201000008482 osteoarthritis Diseases 0.000 title abstract 6
- 101150046889 ADORA3 gene Proteins 0.000 title abstract 2
- 239000003379 purinergic P1 receptor agonist Substances 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 abstract 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229960000485 methotrexate Drugs 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- IPSYPUKKXMNCNQ-PFHKOEEOSA-N (2s,3s,4r,5r)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC(Cl)=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 IPSYPUKKXMNCNQ-PFHKOEEOSA-N 0.000 abstract 1
- HUJXGQILHAUCCV-MOROJQBDSA-N 3-iodobenzyl-5'-N-methylcarboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 HUJXGQILHAUCCV-MOROJQBDSA-N 0.000 abstract 1
- 229940122614 Adenosine receptor agonist Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74063105P | 2005-11-30 | 2005-11-30 | |
| PCT/IL2006/001374 WO2007063538A1 (en) | 2005-11-30 | 2006-11-29 | Use of a3 adenosine receptor agonist in osteoarthritis treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE540673T1 true ATE540673T1 (de) | 2012-01-15 |
Family
ID=37872156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06821594T ATE540673T1 (de) | 2005-11-30 | 2006-11-29 | Verwendung von a3-adenosin-rezeptor-agonisten bei der behandlung von osteoarthritis |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20080300213A1 (de) |
| EP (1) | EP1959939B1 (de) |
| JP (2) | JP5339916B2 (de) |
| KR (1) | KR101101252B1 (de) |
| CN (1) | CN101330909B (de) |
| AT (1) | ATE540673T1 (de) |
| AU (1) | AU2006321165B2 (de) |
| BR (1) | BRPI0619395A2 (de) |
| CA (1) | CA2622879C (de) |
| DK (1) | DK1959939T3 (de) |
| ES (1) | ES2379591T3 (de) |
| WO (1) | WO2007063538A1 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| GB0607944D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607953D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| CA2649215A1 (en) * | 2006-04-21 | 2007-11-01 | Novartis Ag | 2,6,9-trisubstituted purine compounds as adenosine aza receptor modulators |
| EP1889846A1 (de) | 2006-07-13 | 2008-02-20 | Novartis AG | Purinderivate als A2a Agonisten |
| EP1903044A1 (de) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosinderivate als Agonisten des A2A-Rezeptors |
| EP2084121A1 (de) * | 2006-11-10 | 2009-08-05 | Novartis AG | Cyclopentendiolmonoacetatderivate |
| PL2137202T3 (pl) | 2007-03-14 | 2017-12-29 | Can-Fite Biopharma Ltd. | Sposób syntezy IB-MECA |
| IL184620A0 (en) * | 2007-07-15 | 2008-01-20 | Can Fite Biopharma Ltd | Composition for the treatment of inflammation |
| US8916570B2 (en) | 2008-03-31 | 2014-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor agonists and antagonists |
| CA2720037C (en) | 2008-03-31 | 2016-08-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Purine derivatives as a3 adenosine receptor-selective agonists |
| US8796291B2 (en) | 2008-08-01 | 2014-08-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A3 adenosine receptor antagonists and partial agonists |
| US9181253B2 (en) | 2008-08-01 | 2015-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adenosine receptor agonists, partial agonists, and antagonists |
| US10441541B2 (en) * | 2015-09-14 | 2019-10-15 | New York University | Methods and compositions for treating osteoarthritis and promoting cartilage formation |
| IL254535A0 (en) * | 2017-09-17 | 2017-11-30 | Can Fite Biopharma Ltd | Adenosine a3 receptor ligand for use in the management of cytokine release syndrome |
| IL272078A (en) | 2020-01-16 | 2021-07-29 | Can Fite Biopharma Ltd | Cannabinoids for use in treatment |
| CN121045296A (zh) | 2024-05-31 | 2025-12-02 | 康菲特生物制药有限公司 | 制备纳莫德诺森的工艺 |
| EP4670723A1 (de) * | 2024-06-26 | 2025-12-31 | Vetbiolix | Piclidenoson zur verwendung bei der behandlung von osteoarthritis bei nichtmenschlichen säugern |
| CN120183536B (zh) * | 2025-03-06 | 2025-09-02 | 北京大学第三医院（北京大学第三临床医学院） | 抗骨关节炎药物虚拟筛选方法和抗骨关节炎药物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5688774A (en) | 1993-07-13 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
| ATE206432T1 (de) * | 1993-07-13 | 2001-10-15 | Nasa | A3 -adenosin -rezeptor agonisten |
| JP2004135657A (ja) * | 2002-08-21 | 2004-05-13 | Kyowa Hakko Kogyo Co Ltd | ヒトａ３アデノシン受容体を発現するトランスジェニック非ヒト哺乳動物 |
| WO2004045627A1 (en) * | 2002-11-19 | 2004-06-03 | Can-Fite Biopharma Ltd. | A3ar agonists for the treatment of inflammatory arthritis |
| GB0305150D0 (en) * | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Use of therapeutic compounds |
| GB0305153D0 (en) * | 2003-03-07 | 2003-04-09 | Cambridge Biotechnology Ltd | Identification of therapeutic compounds |
| US20060240037A1 (en) * | 2003-06-04 | 2006-10-26 | Edward Fey | Methods and compositions for the treatment and prevention of degenerative joint disorders |
| EP1739097A4 (de) * | 2004-04-02 | 2010-12-08 | Denki Kagaku Kogyo Kk | Hyaluronsäure/methotrexat-verbindung |
| WO2006048884A1 (en) * | 2004-11-08 | 2006-05-11 | Can-Fite Biopharma Ltd. | Therapeutic treatment of accelerated bone resorption |
| US20080051365A1 (en) * | 2004-12-02 | 2008-02-28 | Can-Fite Biopharma Ltd. | Treatment of Inflammation |
| AU2005310873B2 (en) * | 2004-12-02 | 2008-11-27 | Can-Fite Biopharma Ltd. | A biological marker for inflammation |
-
2006
- 2006-11-29 CA CA2622879A patent/CA2622879C/en active Active
- 2006-11-29 BR BRPI0619395-1A patent/BRPI0619395A2/pt not_active Application Discontinuation
- 2006-11-29 US US11/632,897 patent/US20080300213A1/en not_active Abandoned
- 2006-11-29 WO PCT/IL2006/001374 patent/WO2007063538A1/en not_active Ceased
- 2006-11-29 CN CN2006800448083A patent/CN101330909B/zh active Active
- 2006-11-29 DK DK06821594.6T patent/DK1959939T3/da active
- 2006-11-29 KR KR1020087015391A patent/KR101101252B1/ko active Active
- 2006-11-29 AT AT06821594T patent/ATE540673T1/de active
- 2006-11-29 ES ES06821594T patent/ES2379591T3/es active Active
- 2006-11-29 EP EP06821594A patent/EP1959939B1/de active Active
- 2006-11-29 AU AU2006321165A patent/AU2006321165B2/en active Active
- 2006-11-29 JP JP2008542938A patent/JP5339916B2/ja active Active
-
2013
- 2013-05-29 JP JP2013113299A patent/JP2013166789A/ja not_active Withdrawn
-
2016
- 2016-05-20 US US15/160,462 patent/US10265337B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013166789A (ja) | 2013-08-29 |
| EP1959939A1 (de) | 2008-08-27 |
| ES2379591T3 (es) | 2012-04-27 |
| US20160263142A1 (en) | 2016-09-15 |
| CN101330909A (zh) | 2008-12-24 |
| KR20080071609A (ko) | 2008-08-04 |
| BRPI0619395A2 (pt) | 2011-10-04 |
| CN101330909B (zh) | 2012-09-26 |
| EP1959939B1 (de) | 2012-01-11 |
| JP2009517458A (ja) | 2009-04-30 |
| CA2622879C (en) | 2011-07-05 |
| CA2622879A1 (en) | 2007-06-07 |
| DK1959939T3 (da) | 2012-04-23 |
| JP5339916B2 (ja) | 2013-11-13 |
| AU2006321165B2 (en) | 2010-04-22 |
| WO2007063538A1 (en) | 2007-06-07 |
| AU2006321165A1 (en) | 2007-06-07 |
| US20080300213A1 (en) | 2008-12-04 |
| KR101101252B1 (ko) | 2012-01-04 |
| US10265337B2 (en) | 2019-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE540673T1 (de) | Verwendung von a3-adenosin-rezeptor-agonisten bei der behandlung von osteoarthritis | |
| BRPI0912411B8 (pt) | uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune | |
| EA201100079A1 (ru) | Производные триазоло[4,5-d]пирамидина и их применение в качестве антагонистов пуринового рецептора | |
| ATE531263T1 (de) | Hemmer der bruton-tyrosinkinase | |
| EA200800726A1 (ru) | Введение ингибиторов дипептидилпептидазы | |
| CY1112889T1 (el) | Αναλογα αζετιδινης αναστολεων νουκλεοσιδασης και φωσφορυλασης | |
| EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
| BRPI0618918B8 (pt) | uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea | |
| EP1951729A4 (de) | Sauerstoffgebundene pyrimidinderivate | |
| DE602006004844D1 (de) | Pyrrolopyrimidine verwendbar als protein kinase inhibitoren | |
| BRPI0817503B8 (pt) | derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa | |
| ATE459619T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| DE602005019043D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| WO2008023362A3 (en) | Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer | |
| Jackson et al. | The guanosine-adenosine interaction exists in vivo | |
| ATE473961T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| ATE485037T1 (de) | Krebsbehandlung mittels fts und 2-deoxyglucose | |
| ATE277639T1 (de) | Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten | |
| DE60008589D1 (de) | Zusammensetzungen von adenosin a1 agonisten mit 5ht1 agonisten |